N-Benzyltryptamine, also known as T-NB, NB-T, or NBnT, is a serotonin receptor modulator of the tryptamine family. It is the N-benzyl derivative of tryptamine.
N-Benzyltryptamine is not known to have been tested in humans, and it is unknown whether it may produce hallucinogenic effects in humans.
N-Benzyltryptamine shows affinity for the serotonin 5-HT<sub>2</sub> receptors. Its affinities (K<sub>i</sub>) were 245nM for the serotonin 5-HT<sub>2A</sub> receptor, 100nM for the serotonin 5-HT<sub>2B</sub> receptor, and 186nM for the serotonin 5-HT<sub>2C</sub> receptor. In terms of activational activities, specifically calcium mobilization, N-benzyltryptamine's () values were 162nM (62%) at the serotonin 5-HT<sub>2A</sub> receptor and 50nM (121%) at the serotonin 5-HT<sub>2C</sub> receptor. At the serotonin 5-HT<sub>2A</sub> receptor, it had higher affinity than tryptamine, but lower activational potency in comparison. In other studies, at the rat serotonin 5-HT<sub>2A</sub> receptor, N-benzyltryptamine's was 407nM and its was 26%.
The drug has been reported to produce serotonergic psychedelic-like effects in early studies in animals. This included hyperthermia and behavioral changes in the open field test.
Analogues of NbNT include 4-HO-NBnT, 5-MeO-NBnT, 5-MeO-T-NBOMe, 5-MeO-T-NB3OMe, CPI-CG-8, and NEtPhOH-THPI, among others. It is also analogous to N-benzylphenethylamines, for instance 25B-NB (N-benzyl-2C-B), 25I-NBOMe, and benzphetamine (N-benzylmethamphetamine).
N-Benzyltryptamine was first described in the scientific literature by Roger W. Brimblecombe and colleagues by at least 1964. Derivatives of N-benzyltryptamine, such as 5-MeO-T-NBOMe, have subsequently been described as well.